Please try another search
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Name | Age | Since | Title |
---|---|---|---|
Michael D. Webb | - | 2022 | Director |
Frank Pasqualone | - | 2022 | Director |
Bevin O'Neil | - | 2022 | Director |
Michael D. Webb | 65 | 2022 | Independent Chairman of the Board |
Frank Pasqualone | 68 | 2022 | Independent Director |
Maurizio Fava | - | 2022 | Chairman of Scientific Advisory Board |
Michael B. Liebowitz | - | 2022 | Member of Scientific Advisory Board |
George A. Kegler | 68 | 2020 | Independent Non-Employee Director |
Joseph Edward Tucker | 55 | 2021 | CEO & Director |
Marcus Schabacker | 60 | 2020 | Independent Non-Employee Director |
John H. Krystal | - | 2022 | Member of Scientific Advisory Board |
Sheila DeWitt | 63 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review